Julia Osaki, Rei Noguchi, Kazuyoshi Yanagihara, Takuya Ono, Yuki Adachi, Shuhei Iwata, Yu Toda, Tetsuya Sekita, Eisuke Kobayashi, Naoki Kojima, Akihiko Yoshida, Akira Kawai, Tadashi Kondo
Alveolar soft part sarcoma (ASPS) is a rare mesenchymal tumor characterized by rearrangement of the ASPSCR1 and TFE3 genes and a histologically distinctive pseudoalveolar pattern. ASPS progresses slowly, but is prone to late metastasis. As ASPS is refractory to conventional chemotherapy, the only curative treatment is complete surgical resection. The prognosis of advanced and metastatic cases is poor, highlighting the need for preclinical research to develop appropriate treatment options. However, ASPS is extremely rare, accounting for < 1% of all soft tissue sarcomas, and only one patient-derived ASPS cell line is available from public cell banks worldwide for research...
March 13, 2024: Human Cell